EMBECTA CORP. Repayments of Long-Term Debt
EMBECTA CORP. (EMBC) reported Repayments of Long-Term Debt of $77.40 million for the 9-month period ending 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Cash Flow › Financing Activities
us-gaap:RepaymentsOfLongTermDebt · last filed 2026-08-07
- EMBECTA CORP. repayments of long-term debt for the quarter ending 2026-06-30 was $2.40M, a 95.42% decline year-over-year.
- EMBECTA CORP. repayments of long-term debt for the quarter ending 2026-03-31 was $37.50M, a 36.86% increase year-over-year.
- EMBECTA CORP. repayments of long-term debt for the quarter ending 2025-12-31 was $37.50M, a 15.74% increase year-over-year.
- EMBECTA CORP. repayments of long-term debt for the quarter ending 2025-09-30 was $72.40M, a 164.23% increase year-over-year.
- EMBECTA CORP. repayments of long-term debt for fiscal 2025 was $184.60M, a 433.53% increase from fiscal 2024.
- EMBECTA CORP. repayments of long-term debt for fiscal 2024 was $34.60M, a 264.21% increase from fiscal 2023.
- EMBECTA CORP. repayments of long-term debt for fiscal 2023 was $9.50M, a 97.92% increase from fiscal 2022.
- EMBECTA CORP. repayments of long-term debt for fiscal 2022 was $4.80M.
| Period end | Repayments of Long-term Debt 3 month | Repayments of Long-term Debt 6 month | Repayments of Long-term Debt 9 month | Repayments of Long-term Debt 12 month |
|---|---|---|---|---|
| 2026-06-30 | $2.40M derived: 10-Q 9 month − 10-Q 6 month · filed 2026-08-07 | $39.90M derived: sum of 2 quarters · filed 2026-08-07 | $77.40M 10-Q · filed 2026-08-07 | $149.80M derived: sum of 4 quarters · filed 2026-08-07 |
| 2026-03-31 | $37.50M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-05-05 | $75.00M 10-Q · filed 2026-05-05 | $147.40M derived: sum of 3 quarters · filed 2026-05-05 | $199.80M derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-12-31 | $37.50M 10-Q · filed 2026-02-05 | $109.90M derived: sum of 2 quarters · filed 2026-02-05 | $162.30M derived: sum of 3 quarters · filed 2026-08-07 | $189.70M derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-09-30 | $72.40M derived: 10-K 12 month − 10-Q 9 month · filed 2025-11-25 | $124.80M derived: sum of 2 quarters · filed 2026-08-07 | $152.20M derived: sum of 3 quarters · filed 2026-08-07 | $184.60M 10-K · filed 2025-11-25 |
| 2025-06-30 | $52.40M derived: 10-Q 9 month − 10-Q 6 month · filed 2026-08-07 | $79.80M derived: sum of 2 quarters · filed 2026-08-07 | $112.20M 10-Q · filed 2026-08-07 | $139.60M derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-03-31 | $27.40M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-05-05 | $59.80M 10-Q · filed 2026-05-05 | $87.20M derived: sum of 3 quarters · filed 2026-05-05 | $89.60M derived: sum of 4 quarters · filed 2026-05-05 |
| 2024-12-31 | $32.40M 10-Q · filed 2026-02-05 | $59.80M derived: sum of 2 quarters · filed 2026-02-05 | $62.20M derived: sum of 3 quarters · filed 2026-02-05 | $64.60M derived: sum of 4 quarters · filed 2026-02-05 |
| 2024-09-30 | $27.40M derived: 10-K 12 month − 10-Q 9 month · filed 2025-11-25 | $29.80M derived: sum of 2 quarters · filed 2025-11-25 | $32.20M derived: sum of 3 quarters · filed 2025-11-25 | $34.60M 10-K · filed 2025-11-25 |
| 2024-06-30 | $2.40M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-08-08 | $4.80M derived: sum of 2 quarters · filed 2025-08-08 | $7.20M 10-Q · filed 2025-08-08 | $9.60M derived: sum of 4 quarters · filed 2025-11-25 |
| 2024-03-31 | $2.40M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-05-09 | $4.80M 10-Q · filed 2025-05-09 | $7.20M derived: sum of 3 quarters · filed 2025-11-25 | $9.50M derived: sum of 4 quarters · filed 2025-11-25 |
| 2023-12-31 | $2.40M 10-Q · filed 2025-02-06 | $4.80M derived: sum of 2 quarters · filed 2025-11-25 | $7.10M derived: sum of 3 quarters · filed 2025-11-25 | $9.50M derived: sum of 4 quarters · filed 2025-11-25 |
| 2023-09-30 | $2.40M derived: 10-K 12 month − 10-Q 9 month · filed 2025-11-25 | $4.70M derived: sum of 2 quarters · filed 2025-11-25 | $7.10M derived: sum of 3 quarters · filed 2025-11-25 | $9.50M 10-K · filed 2025-11-25 |
| 2023-06-30 | $2.30M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-08-09 | $4.70M derived: sum of 2 quarters · filed 2024-08-09 | $7.10M 10-Q · filed 2024-08-09 | $9.50M derived: sum of 4 quarters · filed 2024-12-11 |
| 2023-03-31 | $2.40M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-05-09 | $4.80M 10-Q · filed 2024-05-09 | $7.20M derived: sum of 3 quarters · filed 2024-12-11 | $9.60M derived: sum of 4 quarters · filed 2024-12-11 |
| 2022-12-31 | $2.40M 10-Q · filed 2024-02-09 | $4.80M derived: sum of 2 quarters · filed 2024-12-11 | $7.20M derived: sum of 3 quarters · filed 2024-12-11 | $7.20M derived: sum of 4 quarters · filed 2024-12-11 |
| 2022-09-30 | $2.40M derived: 10-K 12 month − 10-Q 9 month · filed 2024-12-11 | $4.80M derived: sum of 2 quarters · filed 2024-12-11 | $4.80M derived: sum of 3 quarters · filed 2024-12-11 | $4.80M 10-K · filed 2024-12-11 |
| 2022-06-30 | $2.40M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-08-08 | $2.40M derived: sum of 2 quarters · filed 2023-08-08 | $2.40M 10-Q · filed 2023-08-08 | $2.40M derived: sum of 4 quarters · filed 2023-11-29 |
| 2022-03-31 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-05-12 | $0.00 10-Q · filed 2023-05-12 | $0.00 derived: sum of 3 quarters · filed 2023-11-29 | |
| 2021-12-31 | $0.00 10-Q · filed 2023-02-14 | $0.00 derived: sum of 2 quarters · filed 2023-11-29 | ||
| 2021-09-30 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-11-29 | $0.00 10-K · filed 2023-11-29 | ||
| 2021-06-30 | $0.00 10-Q · filed 2022-08-15 | |||
| 2020-09-30 | $0.00 10-K · filed 2022-12-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| TREACE MEDICAL CONCEPTS, INC. (TMCI) | United States | $0.297B | -4.32 |
| Mobia Medical, Inc. (MOBI) | United States | $0.293B | |
| TriSalus Life Sciences, Inc. (TLSI) | United States | $0.283B | -9.92 |
| SHOULDER INNOVATIONS, INC. (SI) | United States | $0.355B | |
| Orchestra BioMed Holdings, Inc. (OBIO) | United States | $0.356B | -4.39 |
| Cytosorbents Corp (CTSO) | United States | $0.274B | -1.29 |
| ORASURE TECHNOLOGIES INC (OSUR) | United States | $0.272B | -6.26 |
| Anika Therapeutics, Inc. (ANIK) | United States | $0.272B | -51.71 |
| Orthofix Medical Inc. (OFIX) | $0.373B | ||
| InfuSystem Holdings, Inc (INFU) | United States | $0.253B | 22.52 |